Current Research

Clinical Trials

Through understanding the proximate mechanisms that drive eosinophilic gastrointestinal disorders (EGIDs), new pharmaceuticals such as biologics are able to target specific molecular pathways in the treatment of these conditions. At Boston Specialists, we champion several clinical trials in various phases to test for efficacy and safety. While our primary focus is on EGIDs, we also are interested in GI conditions (such as celiac disease and functional dyspepsia), allergic conditions (such as chronic spontaneous urticaria), and diseases that involve both disciplines (such as mast cell GI disease). Learn more about our active clinical trials below.

Study	Sponsor	Diagnosis	Age Range	Pharmaceutical	Route/Frequency	Study Duration	Open-Label	Status
PRV-015-002b	Provention Bio	Celiac disease	18-70	PRV-015	Subcutaneous Injection/Biweekly	9 Months	N/A	Active, Enrolling
2021-GIHF-21-04	GI Health Foundation (GIHF)	CSID	≥18	Sucraid	Solution with each meal	1 Month	1 Week	Active, Enrolling
SSDXA-014	QOL Medical	Fructan Intolerance	≥18	Sucraid	Solution with each meal	1 Month	1 Year	Active, Enrolling
SP-1011-005	Ellodi Pharmaceuticals	Eosinophilic esophagitis	≥18	Fluticasone	Oral Tablet/Nightly	6 Months	Until FDA Approval	Active, Enrolling
SP-1011-004	Ellodi Pharmaceuticals	Eosinophilic esophagitis	≥12	Fluticasone	Oral Tablet/Nightly	Until FDA Approval	Until FDA Approval	Active, Enrolling
CDX0159-08	Celldex Therapeutics	Eosinophilic Esophagitis	≥ 18	Barzolvolimab	Subcutaneous Injection/Q8W	28 weeks	12 weeks	Active, Enrolling
CROSSING	AstraZeneca	Eosinophilic Esophagitis	≥18	Tezepelumab	Subcutaneous Injection/Once Per Month	One Year	6+ months	Active, Enrolling
R668-EGE-2213	Regeneron	Eosinophilic gastritis	≥18	Dupilumab	Subcutaneous Injection/Once Per Week	15 months	24 weeks	Active, Enrolling
IM047-029	Bristol Myers Squibb	Ulcerative colitis	≥18	Ozanimod	Oral Tablet/Daily	12 months	N/A	Active, Enrolling
PT-01	ALK Abelló	Peanut Allergy	18-65	SLIT Tablet	SLIT Tablet/Daily	2 weeks	N/A	Active, Enrolling
GSK3511294	GlaxoSmithKline	Hypereosinophilic syndrome	≥18	Depemokimab	Subcutaneous Injection/Every 6 months	12 months	N/A	Active, Enrolling
CC-93538-EE-001	Bristol Myers Squibb	Eosinophilic esophagitis	18-75	CC-93538/Cendakimab	Subcutaneous Injection/Weekly	16 Months	6 Months	Closed for Enrollment
AK002-018	Allakos	Atopic Dermatitis	18-80	AK002/Lirentelimab	Subcutaneous Injection/Biweekly	9 Months	3 Months	Closed for Enrollment
AK002-027	Allakos	Chronic Spontaneous Urticaria	≥18	AK002	Subcutaneous Injection/Biweekly	9 months	3 months	Closed for Enrollment

Other Research Interests

What are barriers to care for patients with eosinophilic esophagitis/eosinophilic gastrointestinal disorders? Eosinophilic esophagitis and other eosinophilic gastrointestinal disorders are relatively rare diseases, but with increasing prevalence in the United States. As rare but chronic conditions, they can be difficult to manage, as many patients may face issues accessing the care that they need. At Boston Specialists, we are passionate about identifying these barriers and identifying ways to move past them. We have developed and distributed the first emergency action plan for EOE patients and their responding emergency department physicians. Additionally, we outlined our protocol for compassionate infusion of study drugs in private practice settings to expand access for EGID patients.

How can we revolutionize the first-line therapies for eosinophilic esophagitis (EoE) patients? As our understanding of EoE rapidly grows, our standard of care for EoE patients should evolve with it. At Boston Specialists, we are interested in expanding current guidelines to be more patient-centered and focus on treatment plans that are more congruent with patient values. As such, our current research supports more options for maintenance therapy options to histologically and symptomatically control patient’s EoE. Additionally, we have investigated the efficacy of combination therapies in patients with EoE who have failed first-line treatment options.